Chong Yu to Protein Kinase Inhibitors
This is a "connection" page, showing publications Chong Yu has written about Protein Kinase Inhibitors.
Connection Strength
1.999
-
Non-small cell lung cancer harbouring non-resistant uncommon EGFR mutations: Mutation patterns, effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors and prognostic factors. Eur J Cancer. 2019 09; 119:77-86.
Score: 0.386
-
Incidence of hepatitis B reactivation during epidermal growth factor receptor tyrosine kinase inhibitor treatment in non-small-cell lung cancer patients. Eur J Cancer. 2019 08; 117:107-115.
Score: 0.383
-
Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations. Int J Cancer. 2019 06 01; 144(11):2887-2896.
Score: 0.370
-
Treatment effectiveness and tolerability of afatinib at different doses in patients with EGFR-mutated lung adenocarcinoma: How low can we go? Eur J Cancer. 2018 11; 103:32-40.
Score: 0.362
-
Gefitinib or erlotinib in previously treated non-small-cell lung cancer patients: a cohort study in Taiwan. Cancer Med. 2017 Jul; 6(7):1563-1572.
Score: 0.332
-
Best Response According to RECIST During First-line EGFR-TKI Treatment Predicts Survival in EGFR Mutation-positive Non-Small-cell Lung Cancer Patients. Clin Lung Cancer. 2018 05; 19(3):e361-e372.
Score: 0.087
-
Predictive factors for EGFR-tyrosine kinase inhibitor retreatment in patients with EGFR-mutated non-small-cell lung cancer - A multicenter retrospective SEQUENCE study. Lung Cancer. 2017 02; 104:58-64.
Score: 0.080